Find out how MIRAPEX
helps achieve a 50% reduction in motor complications
Learn more
MIRAPEX added nearly
2 hours of "on" time
Learn more

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

Managing Parkinson's disease at every stage

Parkinson's disease is a progressive, long-term condition that significantly impacts the lives of patients and their families13,33

  • Parkinson's disease is a neurodegenerative condition that significantly impacts activities of daily living (ADLs)12,33
  • More than 1 million Americans suffer from PD34
  • Factors affecting treatment include concomitant conditions and treatments, and varying functional abilities12,13
  • 60% to 80% of dopaminergic neurons are lost by the time of initial PD diagnosis35

When initiating PD therapy, it is important to manage motor symptoms while minimizing or delaying motor complications

Motor symptoms are caused by the loss of dopamine-producing neurons in the midbrain (ie, substantia nigra)13

  • Motor symptoms of PD become more severe as neuronal loss progresses
  • Key motor symptoms of PD include: bradykinesia (ie, slowed movement); tremor (ie, shaking); rigidity (ie, stiffness); loss of postural reflexes (ie, difficulty with balance)

Motor complications are a possible consequence of long-term dopaminergic therapy1,13

  • Levodopa may be associated with motor complications sooner and more frequently than other dopaminergic therapies13
  • Major motor complications of dopaminergic therapy include: wearing-off (shorter periods of time a dose of medication is effective); "on"-"off " fluctuations (periods when a patient responds well to medication or when symptoms partially or totally return); dyskinesias (involuntary movements)13
  • Treatment strategies that minimize or delay motor complications may extend the therapeutic window1

Dopamine agonists: established efficacy for both early and advanced PD1,2,4,5

  • Treat motor symptoms, tremor, and ADLs2,4
  • Can help reserve the use of levodopa until patients need it most, which may delay the onset of fluctuations and dyskinesias of levodopa therapy1,5,13
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.